We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
Pfizer and Eli Lilly announced top-line results showing that the high dose of the NGF inhibitor tanezumab met two of three co-primary efficacy endpoints in a Phase III study……